Senseonics
Senseonics (NASDAQ: SENS) is a Germantown, Maryland-based medical technology company that develops and commercializes the Eversense line of long-term implantable continuous glucose monitoring systems, including the world's first and only 365-day CGM, serving adults with Type 1 and Type 2 diabetes.
- Company typePublic
- Founded1997
- HeadquartersGermantown, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Senseonics does
Senseonics Holdings, Inc. is a publicly traded medical technology company (NASDAQ: SENS) headquartered in Germantown, Maryland, that designs, develops, manufactures, and commercializes long-term implantable continuous glucose monitoring (CGM) systems for adults with Type 1 and Type 2 diabetes. Its flagship product, Eversense 365, is the world's first and only FDA-cleared and CE-marked one-year implantable CGM, consisting of a subcutaneous fluorescence-based sensor, a removable rechargeable smart transmitter that sends glucose readings every five minutes to a mobile app, and a companion software layer. The company also sells Eversense E3, a 180-day predecessor system, and is developing a next-generation mobile application with Welldoc that will add AI-powered bolus calculation, medication management, and metabolic tracking.
The business sells hardware (sensors and transmitters) through prescription-based channels with pricing that is not publicly disclosed and reimbursement subject to payer prior authorization. Effective January 1, 2026, Senseonics transitioned from a global distribution partnership with Ascensia Diabetes Care to a fully in-house commercial organization, supplemented by a U.S. distribution agreement with Edgepark and direct field sales targeting endocrinologists, primary care physicians, IDNs, and group practices. Following CE Mark approval in January 2026, the company is launching direct commercial operations in Sweden, Germany, Spain, and Italy. Integration with Sequel Med Tech's twiist automated insulin delivery system (commercial availability February 2026) extends the offering into closed-loop diabetes management.
In FY2025, Senseonics generated $35.3 million in revenue, up 57% year-over-year, with Q4 2025 revenue of $14.3 million (72% YoY) reflecting 103% new patient growth following DTC marketing investment. Management is guiding FY2026 revenue of $58-$62 million (65-76% growth), supported by approximately $157 million in pro forma cash following $172 million of equity offerings in 2026 and an expanded $140 million Hercules Capital debt facility. The company continues to operate at an EBITDA loss as it scales commercial infrastructure and funds the next-generation Gemini sensor pivotal trial.
Senseonics firmographics
Firmographics- Name
- Senseonics
- Legal name
- Senseonics, Incorporated
- Website
- https://senseonics.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Senseonics (NASDAQ: SENS) is a Germantown, Maryland-based medical technology company that develops and commercializes the Eversense line of long-term implantable continuous glucose monitoring systems, including the world's first and only 365-day CGM, serving adults with Type 1 and Type 2 diabetes.
- Ownership category
- akta.pro rank
Senseonics industry classification
Industry- Product category
- Continuous Glucose Monitoring (CGM) Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
- akta.pro secondary industries
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL)
Keywords
Where Senseonics is headquartered
LocationHeadquarters
- HQ city
- Germantown
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Senseonics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain
Revenue model
- Eversense 365 Sensor Sales: Sale of implantable glucose sensors that last up to 365 days. Patients require one sensor insertion per year. Sensors are sold through direct commercial organization and distribution partners.
- Smart Transmitter Sales: Sale of removable and rechargeable smart transmitter worn over the sensor. Transmitter sends glucose data automatically every 5 minutes to mobile app.
- Eversense E3 Sensor Sales: Sale of 180-day implantable CGM sensor (Eversense E3) as alternative product line for patients requiring shorter-term monitoring.
- Distribution Partnership Revenue: Revenue from Ascensia Diabetes Care partnership for global distribution of Eversense products, transitioning to Senseonics direct sales in 2026.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Eversense 365 System (365-day sensor) |
| Other | Pay-as-you-go | Eversense E3 System (180-day sensor) |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels5 records
Senseonics product offering
Product offeringCore offering
Senseonics designs, develops, manufactures, and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with Type 1 and Type 2 diabetes, anchored by the Eversense 365 — the world's first and only one-year implantable CGM, FDA-cleared September 2024 and CE-marked January 2026. The system combines a subcutaneous fluorescence-based sensor inserted by a healthcare provider, a removable rechargeable smart transmitter that sends glucose data every five minutes to a mobile app, and weekly calibration requirements.
Product overview
Senseonics develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company's product portfolio centers on the Eversense platform, comprising the flagship Eversense 365 (365-day sensor) as the world's first and only one-year CGM, and Eversense E3 (180-day sensor). Both products include an implantable sensor inserted under the skin, a removable rechargeable smart transmitter worn externally, and a companion mobile application. The Eversense systems are complemented by the next-generation mobile application being developed with Welldoc, which will enhance user experience and add AI-powered features including CGM-informed bolus calculation and metabolic tracking. The portfolio represents a differentiated approach to diabetes management with significantly longer sensor lifespans compared to traditional 10-14 day CGMs.
Differentiator
Problem solved
Functional benefit
Brands
- Eversense: Long-term implantable continuous glucose monitoring system brand
- Eversense 365
- Eversense E3
- twiist
Products and services
- Eversense 365 Continuous Glucose Monitoring System The world's first and only one-year implantable continuous glucose monitoring (CGM) system. A small fluorescence-based sensor is inserted completely under the skin and communicates with a removable rechargeable smart transmitter worn externally, which sends glucose data automatically every five minutes to a mobile app. Indicated for up to 365 days for adults with Type 1 and Type 2 diabetes aged 18 and older.
- Eversense E3 Continuous Glucose Monitoring System Long-term implantable CGM system providing continuous glucose monitoring for up to 180 days. Includes a subcutaneously inserted sensor, smart transmitter, and mobile app for real-time diabetes monitoring. Predecessor to Eversense 365 with daily calibration requirements after day 21.
- Eversense Smart Transmitter Removable, rechargeable smart transmitter worn externally over the Eversense implantable sensor. Powers the sensor, transmits glucose readings every five minutes to the companion mobile app, and provides on-body vibration alerts for hypoglycemic and hyperglycemic events even when the user's phone is out of sight.
- Next-Generation Eversense 365 Mobile Application A next-generation mobile application being co-developed with Welldoc for the Eversense 365 CGM system. Will offer an enhanced user interface, improved integration with Apple Health and Google Health Connect, support for the twiist Automated Insulin Delivery System, and AI-powered features including CGM-informed bolus calculation, medication management, and metabolic tracking.
Quantifiable outcome
- 93.8% average transmitter wear time across 5,059 real-world sensors over one year
- +4 more outcomes
Companies that use Senseonics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Senseonics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability2 records
Feature7 records
Senseonics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- WelldoccoreStrategic partnership to develop a next-generation mobile application for the Eversense 365 CGM system. The new app will maintain existing features while adding capabilities to enhance user experience and integrate with Apple Health and Google Health Connect. Welldoc's AI platform will enable CGM-informed bolus calculation, medication management, and metabolic tracking features. US launch expected in H2 2026.
- Ascensia Diabetes CarecoreTransition of commercialization and distribution rights from Ascensia Diabetes Care back to Senseonics completed January 1, 2026. Ascensia was global distribution partner for Eversense products. Senseonics assumed full commercial control to accelerate rollout and expand globally, including recapture of revenue share and acquisition of key sales staff.
- EdgeparkminorDistribution partnership expanding patient access to Eversense 365 one-year implantable CGM system. Edgepark offers products addressing gaps in insurance coverage for diabetes management.
- Sequel Med TechcoreCommercial development partnership to integrate Sequel's twiist Automated Insulin Delivery System with Senseonics' Eversense 365 one-year CGM. twiist is the first AID system compatible with Eversense 365, enabling closed-loop diabetes management. Full commercial availability announced February 2026. twiist uses iiSure technology and is powered by Tidepool Loop algorithm.
Scale indicators11 records
Recent moves9 records
Expansion highlights7 records
Senseonics competitors and assessment
Company assessmentEmerging players
- Tidepool: Diabetes data platform powering the twiist AID algorithm integrated with Eversense. Adjacent ecosystem partner relevant to Senseonics' digital and AID strategy.
- Sequel Med Tech: Maker of the twiist AID system integrated with Eversense 365. Strategic partner rather than direct competitor, but operates in the same Type 1 closed-loop ecosystem and shares patient/HCP targeting.
- Welldoc: Digital health/AI platform partnered with Senseonics to build the next-generation Eversense 365 mobile app with bolus calculation and metabolic tracking. Strategic partner in the digital therapeutics layer.
Broad incumbents
- Insulet: Omnipod patch pump maker with strong AID offering (Omnipod 5). Competes for Type 1 share alongside Eversense via AID integrations with Dexcom and Abbott.
- Ascensia Diabetes Care: Former global commercialization partner for Eversense; now a former distributor. Operates broadly in diabetes (blood glucose monitoring, Contour Next) with overlapping patient/provider touchpoints.
- Roche Diabetes Care: Broad diabetes management player (Accu-Chek blood glucose monitoring, insulin delivery systems). Overlaps in the diabetes patient/provider ecosystem with Senseonics.
- LifeScan: Blood glucose monitoring franchise (OneTouch) with established diabetes patient relationships and pharmacy distribution. Adjacent competitor for diabetes monitoring share.
Direct peers
- Dexcom: Leading CGM manufacturer (G6, G7) competing head-to-head with Eversense in Type 1 and Type 2 diabetes markets. Same product category, same HCP and DTC channels, same patient population; much larger scale and broader payer coverage.
- Abbott Diabetes Care: Maker of FreeStyle Libre 2/3/3 Plus, the dominant CGM franchise globally. Directly competes with Eversense and is also an option within the twiist AID system, making it both a competitor and an indirect ecosystem partner.
- Medtronic Diabetes: Integrated CGM and insulin pump manufacturer (Guardian CGM, MiniMed AID systems). Competes with Eversense in the integrated CGM segment and the Type 1 closed-loop population Senseonics targets via twiist.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Senseonics social profiles
Digital presenceSenseonics compliance and trust
Trust signalCompliance3 records
Senseonics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Senseonics leadership team
Management profileNumber of profiles
Profiles8 records
Senseonics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Senseonics funding detail
Funding detailFunding overview
Funding rounds19 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Senseonics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Senseonics
What does Senseonics do?
Senseonics designs, develops, manufactures, and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with Type 1 and Type 2 diabetes, anchored by the Eversense 365 — the world's first and only one-year implantable CGM, FDA-cleared September 2024 and CE-marked January 2026. The system combines a subcutaneous fluorescence-based sensor inserted by a healthcare provider, a removable rechargeable smart transmitter that sends glucose data every five minutes to a mobile app, and weekly calibration requirements.
Is Senseonics a public or private company?
Senseonics is a public company. It is classified as public and is currently operating.
When was Senseonics founded?
Senseonics was founded in 1997. It employs 101 to 250 people.
Where is Senseonics based?
Senseonics is headquartered in Germantown, United States, in the North America region.
How does Senseonics make money?
Four revenue lines are on record. Eversense 365 Sensor Sales are the primary driver. The others are smart Transmitter Sales, eversense E3 Sensor Sales and distribution Partnership Revenue.
Who are Senseonics's main competitors?
Emerging players on record are Tidepool, Sequel Med Tech and Welldoc. Broad incumbents are Insulet, Ascensia Diabetes Care, Roche Diabetes Care and LifeScan. Direct peers are Dexcom, Abbott Diabetes Care and Medtronic Diabetes.
Does Senseonics have an API?
No public API is recorded for Senseonics.
What industry is Senseonics in?
Senseonics's product category is Continuous Glucose Monitoring (CGM) Medical Devices. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 334510 and its SIC code is 3845.